Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
about
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Receptor-Mediated Drug Delivery Systems Targeting to GliomaNew approaches for cancer immunotherapy.Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.IL13RA2 targeted alpha particle therapy against glioblastomas.Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Immune and viral therapies for malignant primary brain tumors.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker.Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma.Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma.Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.Glioblastoma Treatments: An Account of Recent Industrial DevelopmentsCAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
P2860
Q34177641-04F31E42-6426-469E-B4AC-FE2B3DFAAB89Q36082516-AE59D385-3516-465B-A10A-0DA28CCFBE1BQ36248008-9D40EAD1-1AF3-4F0D-82A8-0A0894295FE1Q37636271-D85A841A-AF2C-4CCC-9EA3-1A64CD8C2D51Q38454347-84D3F1B1-47CA-4630-8F08-D97CD7D8EF41Q38526550-DFC1F45A-110D-4D9C-855A-996A0ED0B55DQ38754116-EC83DE4D-FFF3-448B-A85B-85ACB6D7C0F5Q38849515-9C0FCAB5-00B7-4862-B484-4E1843234FAFQ38987239-F89F7AD5-E92E-44D3-98B0-4C798314BC65Q39168899-1A4F1436-C5B5-4B7C-BAD7-88078D066CE7Q39280002-4D0361B3-CD0B-4A22-B2B9-068B277B7283Q41022992-B675BB93-1E47-446F-9535-F5CDEE06B5B9Q41612568-E5A23A45-D634-4F2C-9B22-97DB3A2CD866Q45074720-605E2B3A-EDCC-4D39-A84A-D9EC16291A24Q45867084-93D08947-2EA5-402E-97AB-62E24DEF1476Q47425171-33D8DDB6-1E91-49C2-A5AD-3380D6C64DF6Q47561397-E0008593-B74E-47AE-BB81-5A2B1924EA13Q47565868-0D1DD3D1-8187-4EDE-8AAD-0475AE580067Q52604632-DA64C4B8-E3B6-4A5B-84F2-C924048A8B24Q55358019-1EC04E60-CE96-4089-8043-4AE141D48BC6Q57111067-5867E90F-75BB-47CA-81ED-53A3ABD0FAEDQ57291659-D311ED5E-CE2D-424D-9881-A62AA282D503
P2860
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
@en
type
label
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
@en
prefLabel
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
@en
P2093
P2860
P356
P1433
P1476
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
@en
P2093
Bart Thaci
Emanuela Binello
Katherine Werbaneth
Prakash Sampath
Sadhak Sengupta
P2860
P304
P356
10.1093/NEUONC/NOU045
P577
2014-04-10T00:00:00Z